SGS expands stability capacity at Mississauga, Canada laboratory
Expansion part of global investment in testing capabilities.
SGS has expanded storage capacity at its laboratory in Mississauga, Canada, for the effective stability testing of new drug substances and products for full regulatory compliance. The investment has seen the total storage capacity increase by nearly 200 cubic meters, to an overall total of approximately 450 cubic meters.
The additional capacity is split between six new chambers, which cover four standard storage conditions: 2-8 °C, -20 °C, 30 °C/65% relative humidity, and 40 °C/75% relative humidity. The chambers operate using a fully validated dual redundant cooling system with switch-over capability to ensure zero excursion in the event of mechanical failure, and are supported by gas-powered backup generators in the event of a prolonged power outage.
“We have seen a strong growth in demand for these services, not only from the biopharmaceuticals market, but also within the small molecule space,” commented Michael Lindsay, Vice President – Life Sciences Canada. “The additional capacity this expansion brings will allow us to reconfigure our existing assets to provide the standard frozen, refrigerated, accelerated and intermediate stability conditions, as well as to provide capacity for custom conditions.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.